Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab
Recently, the stabilization of the endothelium has been explicitly identified as a therapeutic goal in coronavirus disease 2019 (COVID-19). Adrecizumab is a first-in-class humanized monoclonal anti-Adrenomedullin (anti-ADM) antibody, targeting the sepsis- and inflammation-based vascular and capillar...
Main Authors: | Mahir Karakas, Dominik Jarczak, Martin Becker, Kevin Roedl, Marylyn M. Addo, Frauke Hein, Andreas Bergmann, Jens Zimmermann, Tim-Philipp Simon, Gernot Marx, Marc Lütgehetmann, Axel Nierhaus, Stefan Kluge |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/8/1171 |
Similar Items
-
Adrenomedullin as a modulator of human trophoblast invasion
by: Wong, Siu-tak., et al.
Published: (2013) -
Prognostic Value of Bioactive Adrenomedullin in Critically Ill Patients with COVID-19 in Germany: An Observational Cohort Study
by: Tim-Philipp Simon, et al.
Published: (2021-04-01) -
Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness
by: Oscar H. M. Lundberg, et al.
Published: (2020-11-01) -
New factors that affect adrenomedullin expression
by: Wong, Hoi-kin, et al.
Published: (2014) -
Human adrenomedullin and its binding protein attenuate tissue injury and inflammation following hepatic ischemia reperfusion in rabbits
by: Asha Jacob, et al.
Published: (2021-08-01)